▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #508 by analyst upside · 2026-09-28
PYXS
Pyxis Oncology, Inc.
Healthcare · Market Cap $239M · P/E 0x
ANALYST PRICE TARGET
+203.0%
implied upside to consensus target
Current Price $2.86
Consensus Target $8.67
Bull Target $19.0
Bear Target $6.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
7
Hold
1
Sell
0
52-Week Low $1.03
52-Week High $5.55
YTD Return +148.7%
FUNDAMENTALS
Market Cap $239M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.40
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $11M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.03
52-Week High $5.55
Current Price $2.86
Bear Target $6.0
Bull Target $19.0
● Now $2.86 ● Target $8.67
TRADING DATA
Avg Volume 1.2M
YTD Return +148.7%
Analyst Count 9
Consensus Buy
Upside to Target +203.0%
Last Updated 2026-09-28

ANALYST SUMMARY

Pyxis Oncology, Inc. (PYXS) is currently trading at $2.86 with a Wall Street consensus price target of $8.67, implying potential upside of 203.0% over the next 12 months. 9 analysts currently cover PYXS, with a consensus rating of Buy - 89% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $19.0, while the most cautious has a target of $6.0.

PYXS operates in the Healthcare sector with a market capitalisation of $239M. The stock is up 148.7% year-to-date and is currently trading near the lower end of its 52-week range of $1.03 – $5.55.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PYXS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wedbush - Reiterated
Outperform → Outperform 2026-09-10 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-09-10 31% win rate (48 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-09-09 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-08-18 31% win rate (48 calls)
Wells Fargo ● Initiated
Overweight 2026-08-03 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-07-02 29% win rate (7 calls)
Wedbush ● Initiated
Outperform 2026-05-05 Building track record
Stifel - Reiterated
Buy → Buy 2026-03-24 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →